Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

CING vs DRMA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CING Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 5–1 Matrix Metrics)

CING Overall Winner 6-Pillar Tally: CING 3 – 1 DRMA (2 Tie) Matrix Metrics: CING 5 – 1 DRMA

As of Nov 17, 2026, Cingulate Inc. (CING) is the stronger overall head-to-head candidate over Dermata Therapeutics, Inc. (DRMA) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). CING carries a Unified Composite Score of 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin), whereas DRMA carries 43.8/100 (HOLD) at $0.58 (N/M Forward P/E, -13082.3% operating margin).

  • Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.8); meanwhile DRMA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CING vs DRMA
CING NASDAQ Head-to-Head Winner
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap $62.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.13β · 117% Vol
Unified Composite Score
44.8 / 100 HOLD
Tech 31.0 Fund 50.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 51.8 · SMA20: $4.71 · SMA50: $4.82
DRMA NASDAQ
Dermata Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.58
-3.14% 1D
Market Cap $3.1M
TTM Revenue $74,137
Forward P/E N/M
Beta / 30D Vol 1.10β · 112% Vol
Unified Composite Score
43.8 / 100 HOLD
Tech 33.0 Fund 46.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.5%), weak momentum, RSI 32
RSI-14: 32.0 · SMA20: $0.75 · SMA50: $0.94

6-Pillar Scorecard Institutional Category Breakdown (CING 3 – 1 DRMA)

Columns: Metric · CING · DRMA
1. Valuation Multiples DRMA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 41.3x
2. Growth & Scale Tie
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $74,137
Market Cap $62.5M $3.1M
3. Profitability & Quality CING
Gross Margin N/A 54.1%
Operating Margin 0.0% -13082.3%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -198.7% -241.5%
4. Balance Sheet & Cash Flow CING
Cash Generation (TTM) -$21M -$7.9M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $22M Net Cash $0.79 Book/Sh · -241.5% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CING
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 111.1% (16th %ile) N/A (N/A)
Put/Call OI Skew 0.07x (Call-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CING (5) vs DRMA (1)
Institutional Metric CING DRMA Criterion Row Edge
Market Capitalization
Scale
$62.5M $3.1M Larger Scale CING
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% -13082.3% Higher Margin CING
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-198.7% -241.5% Higher ROE CING
52-Week Range Position
Momentum
18% ($3–$12) 0% ($1–$5) Stronger Trend CING
Beta / 30D Volatility
Risk Regime
1.13β · 117% Vol 1.10β · 112% Vol Lower Realized Risk DRMA
Unified Institutional Score
Composite Signal
44.8 / 100 (HOLD) 43.8 / 100 (HOLD) Higher Composite CING
Trailing 12M Revenue (USD)
Operating Scale
N/A $74,137 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 54.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 41.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$21M ($22M Net Cash) -$7.9M EBITDA ($0.79 Book/Sh · -241.5% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CING +41.76 pp
CING: +9.17% · DRMA: -32.59%
3M Horizon CING +50.88 pp
CING: -9.68% · DRMA: -60.56%
6M Horizon CING +59.3 pp
CING: +8.43% · DRMA: -50.87%
1Y Horizon CING +117.51 pp
CING: +36.39% · DRMA: -81.12%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs DRMA. Trailing 12-month operating profitability (CING 0.0% vs DRMA -13082.3%) and valuation multiples (CING N/M vs DRMA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CING ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-198.7% · N/M
DRMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$74,137
Gross Margin54.1%
Op. Margin-13082.3%
ROE / Fwd P/E-241.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CING BREAKDOWN
170d in phase · OBV ACCUMULATION
Current IV 111.1%
IV Percentile 16th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CING Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DRMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DRMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CING Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $62.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DRMA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.1M market capitalization and -13082.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CING vs DRMA Key Questions & Quantitative Answers

As of Nov 17, 2026, Cingulate Inc. (CING) is the stronger overall head-to-head candidate over Dermata Therapeutics, Inc. (DRMA) in the Tradestie Institutional Equity Comparison Engine, winning 5–1 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). CING carries a Unified Composite Score of 44.8/100 (HOLD) at $4.76 (N/M Forward P/E, 0.0% operating margin), whereas DRMA carries 43.8/100 (HOLD) at $0.58 (N/M Forward P/E, -13082.3% operating margin). Technical & Structure Timing Caution: CING is currently in a Breakdown options structure phase (RSI 51.8); meanwhile DRMA is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 32.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

CING and DRMA split Growth & Scale metrics: CING posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with DRMA at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $74,137 TTM revenue (54.1% gross margin, -13082.3% operating margin). On trailing 12-month operating scale, CING generates N/A in USD-normalized revenue versus $74,137 for DRMA. In operating R&D and SG&A reinvestment, CING deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DRMA.

DRMA screens cheaper on headline valuation multiples. CING trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas DRMA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 41.3x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CING (-198.7% ROE) versus DRMA (-241.5% ROE) capital efficiency.

In options market volatility and institutional positioning, CING carries 111.1% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.13β · 117% Vol realized risk). By comparison, DRMA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.10β · 112% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.